- Home
- RVMD vs MDGL Comparison
RVMD vs MDGL Comparison
Compare RVMD & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVMD
- MDGL
- Stock Information
- Founded
- RVMD 2014
- MDGL 2011
- Country
- RVMD United States
- MDGL United States
- Employees
- RVMD N/A
- MDGL N/A
- Industry
- RVMD Biotechnology: Biological Products (No Diagnostic Substances)
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- RVMD Health Care
- MDGL Health Care
- Exchange
- RVMD Nasdaq
- MDGL Nasdaq
- Market Cap
- RVMD 7.5B
- MDGL 6.1B
- IPO Year
- RVMD 2020
- MDGL N/A
- Fundamental
- Price
- RVMD $38.11
- MDGL $314.31
- Analyst Decision
- RVMD Strong Buy
- MDGL Strong Buy
- Analyst Count
- RVMD 12
- MDGL 9
- Target Price
- RVMD $68.67
- MDGL $420.63
- AVG Volume (30 Days)
- RVMD 3.3M
- MDGL 282.4K
- Earning Date
- RVMD 08-06-2025
- MDGL 08-06-2025
- Dividend Yield
- RVMD N/A
- MDGL N/A
- EPS Growth
- RVMD N/A
- MDGL N/A
- EPS
- RVMD N/A
- MDGL N/A
- Revenue
- RVMD N/A
- MDGL $317,383,000.00
- Revenue This Year
- RVMD N/A
- MDGL $286.17
- Revenue Next Year
- RVMD $241.39
- MDGL $64.17
- P/E Ratio
- RVMD N/A
- MDGL N/A
- Revenue Growth
- RVMD N/A
- MDGL N/A
- 52 Week Low
- RVMD $29.17
- MDGL $200.63
- 52 Week High
- RVMD $62.40
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- RVMD 47.77
- MDGL 64.53
- Support Level
- RVMD $36.37
- MDGL $284.02
- Resistance Level
- RVMD $38.97
- MDGL $311.21
- Average True Range (ATR)
- RVMD 1.50
- MDGL 11.94
- MACD
- RVMD 0.02
- MDGL 2.74
- Stochastic Oscillator
- RVMD 40.07
- MDGL 100.00
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.